Evidence mapPaperPMID 31869430Full record

Trial reportClinical pharmacology and therapeutics2020

Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.

Diana L Shuster, Laura M Shireman, Xiaosu Ma, Danny D Shen, Shannon K Flood Nichols, Mahmoud S Ahmed, Shannon Clark, Steve Caritis, Raman Venkataramanan, David M Haas and 10 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIComparative Study
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01329016. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01329016 phase1 / phase2completed

Glyburide and Metformin for Gestational Diabetes Mellitus

Ran2011Enrolled177Registered outcomes2Posted comparisons0ConditionsGestational Diabetes MellitusArmsglyburide, Glyburide-Metformin combination, Metformin
PMID 31980499PMID 31742716other papers from this trial
Open the trial in the graph
NCT06589141 nanot yet recruitingstarted 2025, after this paper: background citation

Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes: a Randomized Controlled Trial (GDM-MERGE Trial)

Ran2025Enrolled180Registered outcomes4Posted comparisons0ConditionsGestational Diabetes Mellitus in PregnancyArmsGlyBURIDE 2.5 MG Oral Tablet, MetFORMIN 500 Mg Oral Tablet
PMID 35613728PMID 35195193PMID 22505499other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. The Double-Edged Sword of Gestational Insulin Resistance: Navigating Maternal Adaptation and Its Risks for Pregnancy and Offspring Health.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Diana L ShusterClinical Pharmacology - Scientific Affairs, PRA Health Sciences, Lenexa, Kansas, USA.
Laura M ShiremanDepartments of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Xiaosu MaGlobal PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Danny D ShenDepartments of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Shannon K Flood NicholsDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, Washington, USA.
Mahmoud S AhmedDepartment of Obstetrics & Gynecology, University of Texas Medical Branch in Galveston, Galveston, Texas, USA.
Shannon ClarkDepartment of Obstetrics & Gynecology, University of Texas Medical Branch in Galveston, Galveston, Texas, USA.
Steve CaritisDepartments of Obstetrics & Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-2169-0712
Raman VenkataramananDepartments of Obstetrics & Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
David M HaasDepartments of Obstetrics & Gynecology, Indiana University, Indianapolis, Indiana, USA.
Sara K QuinneyDepartments of Obstetrics & Gynecology, Indiana University, Indianapolis, Indiana, USA.ORCID 0000-0002-6554-0695
Laura S HanelineDepartment of Pediatrics, Indiana University, Indianapolis, Indiana, USA.
Alan T TitaDepartment of Obstetrics & Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Tracy A ManuckDepartment of Obstetrics & Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA.
Kenneth E ThummelDepartments of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Linda Morris BrownRTI International, Environmental, and Health Science Unit, Biostatistics and Epidemiology Division, Rockville, Maryland, USA.
Zhaoxia RenObstetric and Pediatric Pharmacology and Therapeutic Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Zane BrownDepartment of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
Thomas R EasterlingDepartment of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
Mary F HebertDepartment of Obstetrics & Gynecology, University of Washington, Seattle, Washington, USA.
University of Washington · USIndiana University Health · USThe University of Texas Medical Branch at Galveston · USUniversity of Pittsburgh · USEli Lilly (United States) · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USIndiana University Indianapolis · USMadigan Army Medical Center · USPRA Health Sciences · USRTI International · USUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · US

Funding

Pregnancy and Drug Metabolizing Enzymes and TransportersU10HD047905 · MAGEE-WOMEN'S RES INST AND FOUNDATION · 2004 to 2005
$2.4M
Obstetric-Fetal Pharmacology Research Units NetworkU10HD047891 · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · 2004 to 2005
$2.1M
UW Obstetric-Fetal Pharmacology Research UnitU10HD047892 · UNIVERSITY OF WASHINGTON · 2004 to 2005
$1.7M
NCATS NIH HHS TL1 TR000422NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR001108NICHD NIH HHS U10 HD047891NICHD NIH HHS U10 HD047892NICHD NIH HHS U10 HD047905NICHD NIH HHS U10 HD057753NICHD NIH HHS U10 HD063094NICHD NIH HHS U54 HD047905NIGMS NIH HHS R01 GM124264
6 · The paper itself

Abstract

In gestational diabetes mellitus (GDM), women are unable to compensate for the increased insulin resistance during pregnancy. Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy. This study characterized insulin sensitivity (SI), β-cell responsivity, and disposition index (DI) in women with GDM utilizing a mixed-meal tolerance test (MMTT) before and during treatment with glyburide monotherapy (GLY, n = 38), metformin monotherapy (MET, n = 34), or GLY and MET combination therapy (COMBO; n = 36). GLY significantly decreased dynamic β-cell responsivity (31%). MET and COMBO significantly increased SI (121% and 83%, respectively). Whereas GLY, MET, and COMBO improved DI, metformin (MET and COMBO) demonstrated a larger increase in DI (P = 0.05) and a larger decrease in MMTT peak glucose concentrations (P = 0.03) than subjects taking only GLY. Maximizing SI with MET followed by increasing β-cell responsivity with GLY or supplementing with insulin might be a more optimal strategy for GDM management than monotherapy.

Indexed as

AdolescentAdultBlood GlucoseDiabetes, GestationalDrug Therapy, CombinationFemaleGlyburideHumansHypoglycemic AgentsInsulin ResistanceInsulin-Secreting CellsLongitudinal StudiesMetforminPregnancyProspective StudiesYoung AdultBlood GlucoseGlyburideHypoglycemic AgentsMetformin

Identifiers

PMID31869430
PMCPMC7561209
OpenAlexW2995124319

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.